Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Repeated dose toxicity: oral
Administrative data
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 21. January to 04. March 2009
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: Compliant to OECD 407 and GLP guideline
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 009
- Report date:
- 2009
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Limit test:
- no
Test material
- Details on test material:
- Name: DYNS 2246
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Analytical verification of doses or concentrations:
- yes
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- daily
Doses / concentrations
- Remarks:
- Doses / Concentrations:
15.625, 62.5, and 250 mg/mL
Basis:
other: formulation anylytics (UV-HPLC ): 91% to 103% of nominal concentrations
- No. of animals per sex per dose:
- Groups 1 to 4: 5 animals/sex/main group
Groups 1 and 4: 5 animals/sex/recovery group - Control animals:
- yes, concurrent vehicle
Results and discussion
Effect levels
- Dose descriptor:
- NOAEL
- Effect level:
- 1 000 mg/kg bw/day (nominal)
- Sex:
- male/female
- Basis for effect level:
- other: see 'Remark'
Target system / organ toxicity
- Critical effects observed:
- not specified
Applicant's summary and conclusion
- Conclusions:
- DYNS 2246 administered daily by oral gavage for 28 days in Wistar rats did not lead to any mortality or toxicologically significant clinical adverse effects at dose levels of 62.5, 250, or 1000 mg/kg bw/day. During the treatment period (main and recovery animals), dark faeces were observed in animals’ cages at all the dose levels tested for the most part of the study, which partly correlated to test item-related brown discoloration of the digestive content at necropsy. In addition, dark discoloration of the bedding and later on, light pink discoloration of the fur were recorded, as a consequence of the staining effect of the test item. The latter partly correlated to the pink-brown discoloration of the whole body observed in males at necropsy. All findings were reversible within one week after cessation of treatment. All rats were normal at the end of 14-day recovery period, no DYNS 2246-related macroscopic findings were noted at necropsy examination. These changes were ascribed to elimination of DYNS 2246 or its metabolites through faeces; moreover, in the absence of any clinical pathology alterations, they were not considered adverse effects. There were no changes that could be ascribed to DYNS 2246 administration noted in the body weight and body weight gain, animal food consumption, or clinical pathology parameters (haematology, coagulation and clinical chemistry) evaluated at the completion of the 28-day treatment period (all dose levels), or at the end of a 14-day recovery period (control, and 1000 mg/kg bw/day animals). There were no microscopic changes, or changes in the organ weights related to DYNS 2246 administration in either main or recovery animals examined.
In conclusion, the no observed adverse effect level (NOAEL) for DYNS 2246 is considered to be 1000 mg/kg bw/day. - Executive summary:
The objective of this study was to assess the toxicity of DYNS 2246 administered daily for 28 consecutive days by oral gavage to CRL:(WI)BR rats. In addition, reversibility of any treatment-related changes was evaluated following a 14-day recovery period. Sixty Wistar rats (20 male and 20 female Main animals, and 10 male, 10 female Recovery animals) were administered DYNS 2246 according to the following experimental design:
Group No.
Group Designation
Dose
(mg/kg/day)Concentration
(mg/mL)Dose volume
(mL/kg)
Number of Animals
Main
Recovery
M
F
M
F
1
Control (PEG)
0
0
4
5
5
5
5
2
Low Dose
62.5
15.625
5
5
-
-
3
Mid Dose
250
62.5
5
5
-
-
4
High Dose
1000
250
5
5
5
5
Dosages were not corrected for purity or content DYNS 2246.
Parameters measured during the study included observation of clinical signs, performed daily (general, cage side observations, after the dose administration), or weekly (detailed observations), as well as a modified Irwin test conducted on Day 26, body weight and body weight gain, and food consumption. In addition, blood was collected prior to terminal necropsy, for clinical pathology (haematology, coagulation and clinical chemistry) assessment. At termination, necropsy with macroscopic examination was performed, and selected organs were weighed. Histopathology evaluation was conducted on tissues and organs retained in fixative and processed to slides from the control and high dose animals (1000 mg/kg bw/day), and on all organs with macroscopic findings from the low and mid dose groups (62.5 and 250 mg/kg bw/day, respectively). Analysis of formulations (concentration, homogeneity) and assessment of test item stability in this vehicle in the conditions employed on the study was performed in the Analytical Laboratory of LAB Research Ltd.
Stability tests (LAB study code 08/795-316AN) indicated an up to 24 hour stability at room temperature; in addition, under refrigerated conditions (5±3°C), at concentrations from approximately 1 to 250 mg/mL in PEG 400, the solutions were stable for up to 72 hours, with a recovery of 99 and 95%, respectively, within the acceptable range of 100 ± 10%. Concentration and homogeneity of formulations were evaluated by UV-HPLC method on duplicate samples collected from the top, middle and bottom of test item solutions, and one sample from the control, taken and analyzed fresh during the first and last weeks of treatment. Dose formulations were homogenous; the measured (actual) concentrations varied between 91 to 103% of the nominal concentrations; these results were considered suitable for the study purposes.
DYNS 2246 caused neither mortality, nor toxicologically significant systemic clinical changes following administration by oral gavage, daily for 28 days, at up to 1000 mg/kg bw/day in CRL:(WI)BR rats. During the treatment period, dark faeces were observed in animals’ cages at all the dose levels tested from Day 2 (males) or Day 1 (females) onwards. As further consequence of the staining effect of the test item, dark discoloration of the bedding was observed in males at 1000 mg/kg/day from Day 7 onwards and light pink discoloration of the fur in males and females at 250 and/or 1000 mg/kg/day from Day 19 onwards were recorded. Following completion of the treatment at 1000 mg/kg bw/day (recovery animals), the dark discoloration of the bedding observed in the cages of the male animals ceased as of Day 28, while the light pink staining of the animal fur persisted during the first week of post-treatment observation in both sexes. All the animals were normal at the end of the 14-day recovery period. These changes were ascribed to elimination of DYNS 2246 or its metabolites through faeces; moreover, in the absence of any clinical pathology alterations, they were not considered adverse effects. The behaviour and the general condition of the test animals were normal during the study. There was no treatment-related effect on motor activity or in the functional observation battery tests across groups of treated male or female animals and no findings indicative of neurotoxicity were observed. There were no toxicologically significant changes in body weight, body weight gain or animal food consumption between the control and test item treated groups.
Minor variations, on occasion attaining statistical significance, were noted in the clinical pathology parameters (haematology, coagulation, or clinical chemistry) in both main and recovery animals. However, no dose or gender-response was observed, and/or the results were within the historical range. These changes were neither considered toxicologically significant, nor indicated a DYNS 2246-related etiology.
At necropsy of the main animals on Day 28, test item-related brown discoloration of the digestive content was observed in 3/10 and 10/10 rats at dose levels of 250 mg/kg/bw/day and 1000 mg/kg/bw/day, respectively. Pink-brown discoloration of the whole body in 1/5 mid dose (250 mg/kg bw/day) and 5/5 high dose (1000 mg/kg bw/day) males was suggestive of a secondary effect (staining) of DYNS 2246. No similar effect was noted in the females. At the end of the 14-day recovery period, no DYNS 2246-related macroscopic findings were noted. There were no microscopic changes, or changes in the organ weights related to DYNS 2246 administration in either main or recovery animals examined.
In conclusion, under the conditions of this study, the no observed adverse effect level (NOAEL) for DYNS 2246 is considered to be 1000 mg/kg bw/day.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.

Welcome to the ECHA website. This site is not fully supported in Internet Explorer 7 (and earlier versions). Please upgrade your Internet Explorer to a newer version.
This website uses cookies to ensure you get the best experience on our websites.
Find out more on how we use cookies.